Blair William & Co. IL Reduces Stock Holdings in Pfizer Inc. $PFE

Blair William & Co. IL lowered its holdings in shares of Pfizer Inc. (NYSE:PFE) by 18.9% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,858,052 shares of the biopharmaceutical company’s stock after selling 432,146 shares during the quarter. Blair William & Co. IL’s holdings in Pfizer were worth $45,039,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Brighton Jones LLC raised its holdings in Pfizer by 1,282.4% in the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after purchasing an additional 618,117 shares during the period. Revolve Wealth Partners LLC grew its holdings in Pfizer by 12.5% during the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after purchasing an additional 2,087 shares during the period. GAMMA Investing LLC increased its position in Pfizer by 69.0% in the first quarter. GAMMA Investing LLC now owns 63,131 shares of the biopharmaceutical company’s stock worth $1,600,000 after buying an additional 25,785 shares in the last quarter. Integrated Advisors Network LLC raised its stake in shares of Pfizer by 20.9% in the first quarter. Integrated Advisors Network LLC now owns 69,834 shares of the biopharmaceutical company’s stock worth $1,770,000 after buying an additional 12,064 shares during the period. Finally, Donaldson Capital Management LLC lifted its position in shares of Pfizer by 8.6% during the 1st quarter. Donaldson Capital Management LLC now owns 38,772 shares of the biopharmaceutical company’s stock valued at $982,000 after buying an additional 3,078 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on PFE shares. Citigroup increased their target price on shares of Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a research report on Wednesday. Wall Street Zen cut shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. Bank of America lifted their target price on shares of Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research note on Friday, October 3rd. Finally, UBS Group reaffirmed a “neutral” rating and issued a $28.00 target price on shares of Pfizer in a report on Wednesday, October 1st. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $28.41.

Pfizer Price Performance

PFE stock opened at $25.22 on Friday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The company’s fifty day moving average price is $24.83 and its 200-day moving average price is $24.14. Pfizer Inc. has a one year low of $20.92 and a one year high of $30.08. The company has a market capitalization of $143.39 billion, a PE ratio of 13.41, a price-to-earnings-growth ratio of 0.84 and a beta of 0.55.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.58 by $0.20. The company had revenue of $14.65 billion during the quarter, compared to analysts’ expectations of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. Pfizer’s quarterly revenue was up 10.3% on a year-over-year basis. During the same period last year, the company posted $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, equities analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.8%. The ex-dividend date of this dividend is Friday, November 7th. Pfizer’s payout ratio is 91.49%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.